Accéder au contenu
Merck

569396

Staurosporine

from Streptomyces sp., ≥97% (HPLC), liquid, protein kinase inhibitor, Calbiochem

Synonyme(s) :

InSolution Staurosporine, Streptomyces sp., PKA Inhibitor II, MLCK Inhibitor I

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C28H26N4O3
Numéro CAS:
62996-74-1
Poids moléculaire :
466.53
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD00077402

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Staurosporine, Streptomyces sp., InSolution, ≥97%, 1 mM solution, protein kinase inhibitor

SMILES string

[n]21c3c4[n](c6c(c4c7c(c3c8c2cccc8)CNC7=O)cccc6)[C@@H]5O[C@]1([C@@H]([C@@H](C5)NC)OC)C

InChI

1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1

InChI key

HKSZLNNOFSGOKW-FYTWVXJKSA-N

assay

≥97% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

shipped in

wet ice

storage temp.

−70°C

Quality Level

100

Catégories apparentées

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PKA
Product competes with ATP.
Reversible: yes
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively

Disclaimer

Toxicity: Irritant (B)

General description

A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.

Other Notes

Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.
Bruno, S., et al. 1992. Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.
Vitale, M.L., et al. 1992. Neuroscience51, 463.
Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.
Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.

Packaging

Packaged under inert gas

Physical form

A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.

Preparation Note

Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Classe de stockage

10 - Combustible liquids

wgk

WGK 1

flash_point_f

188.6 °F - closed cup - (Dimethylsulfoxide)

flash_point_c

87 °C - closed cup - (Dimethylsulfoxide)

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Shuai Guo et al.
British journal of pharmacology, 179(21), 4974-4991 (2022-07-15)
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models.
Athena Kyrkou et al.
Nature communications, 15(1), 5115-5115 (2024-06-16)
Neurofibromatosis Type II (NFII) is a genetic condition caused by loss of the NF2 gene, resulting in activation of the YAP/TAZ pathway and recurrent Schwann cell tumors, as well as meningiomas and ependymomas. Unfortunately, few pharmacological options are available for
Marco Ponzetti et al.
Frontiers in oncology, 12, 983254-983254 (2022-12-23)
Osteosarcoma is the most common primary bone malignancy. The crosstalk between osteosarcoma and the surrounding tumour microenvironment (TME) drives key events that lead to metastasization, one of the main obstacles for definitive cure of most malignancies. Extracellular vesicles (EVs), lipid
Erin R Spiller et al.
Frontiers in oncology, 11, 771173-771173 (2022-01-08)
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing
Liaisan Arslanbaeva et al.
Redox biology, 51, 102272-102272 (2022-03-08)
Cutaneous melanoma is the deadliest type of skin cancer, although it accounts for a minority of all skin cancers. Oxidative stress is involved in all stages of melanomagenesis and cutaneous melanoma can sustain a much higher load of Reactive Oxygen

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique